deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01944943

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Sponsor: Roche Pharma AG

Conditions Chronic Lymphocytic Leukemia Diffuse Large B-cell Lymphoma Indolent Non-hodgkin Lymphoma Primary Central Nervous System Lymphoma
Interventions Vismodegib
Updated 6 times since 2017 Last updated: Mar 8, 2017 Started: Feb 28, 2013 Primary completion: Aug 31, 2014 Completion: Oct 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

lack of efficacy

Other terminated trials from Roche Pharma AG

More terminations from Roche Pharma AG

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

A PHASE2 clinical study on Chronic Lymphocytic Leukemia and Diffuse Large B-cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Roche Pharma AG and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Roche Pharma AG
  • The Lymphoma Academic Research Organisation
Data source: The Lymphoma Academic Research Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations